Cambridge Oncometrix

A non-invasive prostate cancer risk stratification test.

Cambridge Oncometrix aims to improve and save men's lives by enabling the an early detection of prostate cancer - a condition that is likely to affect 1 in 8 men at some stage of their lives.

We develop an innovative non-invasive diagnostic test for the early detection of prostate cancer. The test is based on measuring changes in the composition of prostatic or seminal fluid, which can be readily measured by technology developed by Cambridge Oncometrix (CAMONX).

In order to establish the existence of a prostate condition the measured values of our proprietary CAMONX biomarkers are combined entered into an index, which and this is provides a very effective indicative of the onset of the disease.

Our test is quick, easy-to-use and reliable and can be performed at home and in medical institutions.